Search

Your search keyword '"Turpeenniemi‐Hujanen, Taina"' showing total 445 results
Start Over Author "Turpeenniemi‐Hujanen, Taina"
445 results on '"Turpeenniemi‐Hujanen, Taina"'

5. Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer : A Secondary Analysis of the SOLD Randomized Clinical Trial

Author

Joensuu, Heikki, Fraser, Judith, Wildiers, Hans, Huovinen, Riikka, Auvinen, Paeivi, Utriainen, Meri, Villman, Kenneth K., Halonen, Paivi, Granstam-Bjorneklett, Helena, Tanner, Minna, Sailas, Liisa, Turpeenniemi-Hujanen, Taina, Yachnin, Jeffrey, Huttunen, Teppo, Neven, Patrick, Canney, Peter, Harvey, Vernon J., Kellokumpu-Lehtinen, Pirkko-Liisa, Lindman, Henrik, Joensuu, Heikki, Fraser, Judith, Wildiers, Hans, Huovinen, Riikka, Auvinen, Paeivi, Utriainen, Meri, Villman, Kenneth K., Halonen, Paivi, Granstam-Bjorneklett, Helena, Tanner, Minna, Sailas, Liisa, Turpeenniemi-Hujanen, Taina, Yachnin, Jeffrey, Huttunen, Teppo, Neven, Patrick, Canney, Peter, Harvey, Vernon J., Kellokumpu-Lehtinen, Pirkko-Liisa, and Lindman, Henrik

Abstract

Importance: The standard adjuvant treatment for patients with ERRB2-positive breast cancer is chemotherapy plus 1 year of trastuzumab. Shorter durations of trastuzumab administration improve cardiac safety, but more information is needed about their effect on survival. Objective: To compare survival outcomes after 9-week vs 1-year administration of trastuzumab with the same adjuvant chemotherapy. Design, Setting, and Participants: This post hoc secondary analysis of an open-label, multicenter, noninferiority-design randomized clinical trial included women aged 18 years or older with early ERBB2-positive, axillary node-negative or axillary node-positive breast cancer who were enrolled from January 3, 2008, to December 16, 2014, at 65 centers in 7 European countries. The current exploratory analysis was conducted after achieving the maximum attainable follow-up data when the last patient enrolled had completed the last scheduled visit in December 2022. Intervention: Chemotherapy consisted of 3 cycles of docetaxel administered at 3-week intervals followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide at 3-week intervals. Trastuzumab was administered in both groups for 9 weeks concomitantly with docetaxel. In the 9-week group, no further trastuzumab was administered after chemotherapy, whereas in the 1-year group, trastuzumab was continued after chemotherapy to complete 1 year of administration. Main Outcomes and Measures: The primary objective was disease-free survival (DFS). Distant DFS and OS were secondary objectives. Survival between groups was compared using the Kaplan-Meier method and log-rank test or univariable Cox proportional hazards regression. Results: Among the 2174 women analyzed, median age was 56 years (IQR, 48-64 years). The median follow-up time was 8.1 years (IQR, 8.0-8.9 years); 357 DFS events and 176 deaths occurred. Trastuzumab for 9 weeks was associated with shorter DFS compared with trastuzumab for 1 year (hazard ratio [HR], 1.36

Published
2024
Full Text
View/download PDF

6. Drug‐induced pneumonitis risk in diffuse large B‐cell/follicular lymphoma patients treated with R‐CHOP‐like regimen is associated with the use of granulocyte colony‐stimulating growth factors

Author

Kaprio, Elina, primary, Prusila, Roosa, additional, Tokola, Susanna, additional, Kuusisto, Milla E. L., additional, Jantunen, Esa, additional, Kuitunen, Hanne, additional, Turpeenniemi‐Hujanen, Taina, additional, and Kuittinen, Outi, additional

Published
2024
Full Text
View/download PDF

7. Drug-induced pneumonitis risk in diffuse large B-cell/ follicular lymphoma patients treated with R-CHOP-like regimen is associated with the use of granulocyte colony-stimulating growth factors.

Author

Kaprio, Elina, Prusila, Roosa, Tokola, Susanna, Kuusisto, Milla E. L., Jantunen, Esa, Kuitunen, Hanne, Turpeenniemi-Hujanen, Taina, and Kuittinen, Outi

Subjects
GRANULOCYTE-colony stimulating factor, FOLLICULAR lymphoma, DIFFUSE large B-cell lymphomas, PULMONARY fibrosis, PNEUMONIA, DRUG side effects
Abstract

Background: Rituximab-based combinations are the standard of care in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Despite being on market for over 20 years, some of the adverse effects associated with the use of rituximab are not well known. Drug-induced interstitial pneumonitis (DIP) is a potentially fatal complication of the treatment. Granulocyte colony-stimulating factors (G-CSF) are supportive agents commonly used to prevent neutropenic infections. G-CSF are reported to have pulmonary toxicity, but the risk of DIP is greater when used in combination with other potentially pulmotoxic agents. Methods: In this retrospective study, we reported the G-CSF use and risk of DIP in 234 DLBCL patients and 87 FL patients receiving R-CHOP-type immunochemotherapy. Results: In 72% of patients, the treatment included a G-CSF support. The overall incidence of treatment-induced pneumonitis was 6.9% in this patient group. All the DIP cases (n=16) were among patients receiving G-CSF support (p=0.03). Older age (over 60 years) and higher disease stage (Ann Arbor 3–4) also increased the risk of DIP. Conclusions: These findings suggest that the use of G-CSF increases the risk of DIP, when used in combination with rituximab-containing regimen. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.

Author

Rajamäki, Aino, Sorigue, Marc, Prusila, Roosa E. I., Kuusisto, Milla E. L., Kuitunen, Hanne, Jantunen, Esa, Mercadal, Santiago, Turpeenniemi-Hujanen, Taina, Sancho, Juan-Manuel, Sunela, Kaisa, and Kuittinen, Outi

Subjects
NON-Hodgkin's lymphoma, ACADEMIC medical centers, CANCER patients, DESCRIPTIVE statistics, PROGRESSION-free survival, COMPARATIVE studies, CONFIDENCE intervals, MEDICAL practice
Abstract

Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. Patients and Methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of therapy on the basis of relevant biological characteristics and therapeutic choices. Patients (n = 743, 51% females, median 60 years old) diagnosed with grade 1-2 FL between 1997 and 2016 in nine institutions were included. Results: The median PFS1, PFS2, and PFS3 were 8.1 years (95% confidence interval [CI]: 7-9.3 years), 4.2 years (95% CI: 2.8-5.6 years) and 2.2 years (95% CI 1.7-2.8 years). We found longer PFS1 for (1) females, (2) younger age, (3) lower-risk follicular lymphoma international prognostic index (FLIPI), (4) standard intensity (over low intensity) regimens and (5) immunochemotherapy strategies and (6) maintenance rituximab. We found a shorter PFS2 for patients who received front-line immunochemotherapy. Older age at diagnosis correlated with a shorter PFS3. Intensity of front-line chemotherapy, maintenance, or POD24 status did not correlate with PFS2 or PFS3 in this dataset. Interpretation: With current immunochemotherapy strategies, the natural course of FL is characterized by shorter-lasting remissions after each relapse. It will be interesting to see whether new therapies can alter this pattern. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Supplementary Data from Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening

Author

Sihto, Harri, primary, Lundin, Johan, primary, Lehtimäki, Tiina, primary, Sarlomo-Rikala, Maarit, primary, Bützow, Ralf, primary, Holli, Kaija, primary, Sailas, Liisa, primary, Kataja, Vesa, primary, Lundin, Mikael, primary, Turpeenniemi-Hujanen, Taina, primary, Isola, Jorma, primary, Heikkilä, Päivi, primary, and Joensuu, Heikki, primary

Published
2023
Full Text
View/download PDF

14. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

Author

Kellokumpu-Lehtinen, Pirkko-Liisa, Harmenberg, Ulrika, Joensuu, Timo, McDermott, Ray, Hervonen, Petteri, Ginman, Claes, Luukkaa, Marjaana, Nyandoto, Paul, Hemminki, Akseli, Nilsson, Sten, McCaffrey, John, Asola, Raija, Turpeenniemi-Hujanen, Taina, Laestadius, Fredrik, Tasmuth, Tiina, Sandberg, Katinka, Keane, Maccon, Lehtinen, Ilari, Luukkaala, Tiina, and Joensuu, Heikki

Published
2013
Full Text
View/download PDF

17. The Sample Type used Affects the Levels of Gelatinases (MMP-2 and -9) and their Inhibitors (TIMP-1 and -2) in Circulating Blood of Healthy Controls and Breast Cancer Patients

Author

Kuvaja Paula, Talvensaari-Mattila Anne, and Turpeenniemi-Hujanen Taina

Subjects
preanalytical aspects, ELISA, gelatinases, tissue inhibitor of metalloproteinases, Medicine (General), R5-920
Abstract

New potential tumor markers such as matrix metalloproteinases and their inhibitors have been extensively studied during the last decades. The aim is to find prognostic markers that are measurable in easily available samples, such as serum or plasma. The proper sample type to use when measuring the levels of gelatinases and their inhibitors from blood samples is currently under critical evaluation. In this study, the effect of sample type is studied in 26 healthy controls, and the result is confirmed in a series of 80 breast carcinoma patients. Sample type had the most evident effect on the levels of TIMP-1 and MMP-9. Serum samples gave about two-fold levels of TIMP-1 compared to plasma samples (p < 0.001), with a strong linear correlation between these two (r = 0.79). Pro-MMP-9 levels were significantly affected by the presence of a blood coagulation activator in the serum sample, or a different anticoagulant in the plasma sample. The serum and plasma values had only a weak correlation (r = 0.37). In conclusion, sample type should be carefully considered, especially when measuring proMMP-9, and plasma should be preferred for this measurement. For TIMP-1 the correlation of serum and plasma values is good; the use of serum samples can therefore be justifi ed as long as the generally higher levels in the serum are acknowledged.

Published
2007

29. Levels of Circulating TIMP-2 and MMP2-TIMP2 Complex Are Decreased in Squamous Cervical Carcinoma

Author

Talvensaari-Mattila Anne and Turpeenniemi-Hujanen Taina

Subjects
Gynecology and obstetrics, RG1-991
Abstract

Background. The role of matrix metalloproteinase-2 and -9 (MMP-2, MMP-9) in matrix degradation and metastasis has been described in various tumors. Their action is inhibited by their natural tissue inhibitor molecules TIMP-1 and -2. Methods. The study population consisted of 12 squamous cervical carcinoma patients and 27 healthy volunteer control patients. MMP-9, MMP-2-TIMP-2 complex, TIMP-1, and TIMP-2 were analyzed from serum samples using enzyme-linked immunoassay (ELISA). Results. The mean levels of serum TIMP-2 and of MMP-2-TIMP-2 complex were higher in healthy controls compared to patients with a malignant tumor. Serum TIMP-2 values decreased significantly from healthy controls (median 323 𝜇g/l, range 305–342 𝜇g/l) to malignant (median 136 𝜇g/l, range 120–151 𝜇g/l) squamous cervical carcinoma patients (𝑃

Published
2010
Full Text
View/download PDF

31. Risk for distant recurrence of breast cancer detected by mammography screening or other methods

Author

Joensuu, Heikki, Lehtimaki, Tiina, Holli, Kaija, Elomaa, Liisa, Turpeenniemi-Hujanen, Taina, Kataja, Vesa, Anttila, Ahti, Lundin, Mikael, Isola, Jorma, and Lundin, Johan

Subjects
Mammography -- Usage
Abstract

The objective of this study is comparing the risk of recurrence and survival among women with cancerous tumors, which were detected by mammography screening with other methods outside of screening. It was found that the cancer tumors detected by mammography screening are associated with a better prognosis than tumors of similar size found outside of screening.

Published
2004

41. Testis-Specific Thioredoxins TXNDC2, TXNDC3, and TXNDC6 Are Expressed in Both Testicular and Systemic DLBCL and Correlate with Clinical Disease Presentation

Author

Chan, Mikko C., primary, Savela, Janette, additional, Ollikainen, Riina K., additional, Teppo, Hanna-Riikka, additional, Miinalainen, Ilkka, additional, Pirinen, Risto, additional, Kari, Esa J. M., additional, Kuitunen, Hanne, additional, Turpeenniemi-Hujanen, Taina, additional, Kuittinen, Outi, additional, and Kuusisto, Milla E. L., additional

Published
2021
Full Text
View/download PDF

43. Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma

Author

Kuitunen, Hanne, primary, Kaprio, Elina, additional, Karihtala, Peeter, additional, Makkonen, Ville, additional, Kauppila, Saila, additional, Haapasaari, Kirsi-Maria, additional, Kuusisto, Milla, additional, Jantunen, Esa, additional, Turpeenniemi-Hujanen, Taina, additional, and Kuittinen, Outi, additional

Published
2020
Full Text
View/download PDF

44. Thioredoxin‐1 as a biological predictive marker for selecting diffuse large B‐cell lymphoma patients for etoposide‐containing treatment

Author

Kari, Esa Jarkko Mikael, primary, Kuusisto, Milla Elvi Linnea, additional, Honkavaara, Päivi, additional, Hakalahti, Anna, additional, Haapasaari, Kirsi‐Maria, additional, Bloigu, Risto, additional, Karihtala, Peeter, additional, Teppo, Hanna‐Riikka, additional, Pirinen, Risto, additional, Turpeenniemi‐Hujanen, Taina, additional, and Kuittinen, Outi, additional

Published
2020
Full Text
View/download PDF

46. Sosiaaliset verkostot ja vastasairastuneiden syöpäpotilaiden elämänlaatu

Author

Lehto, Ulla-Sisko, Ojanen, Markku, Turpeenniemi-Hujanen, Taina, Yhteiskuntatieteiden tiedekunta - Faculty of Social Sciences, and Tampere University

Subjects
Syöpätaudit - Cancers, Psykologia - Psychology
Abstract

Tiivistelmä Johdanto: Sosiaaliset verkostot ovat tärkeitä hyvinvointiresursseja. Tutkimme vastasairastuneiden syöpäpotilaiden sosiaalisten verkostojen yhteyttä heidän elämänlaatuunsa. Menetelmät: Mittasimme Oulun yliopistollisen sairaalan (OYS) syöpätautien klinikkaan hoitoon tulleiden 224 rintasyöpä- ja 150 eturauhassyöpäpotilaan sosiaalisia verkostoja (puoliso, perhe, omaiset, ystävät, tuttavat, muut syöpäpotilaat, hoitohenkilökunta, työyhteisöjen jäsenet, osallistuminen harrastus- tai järjestötoimintaan) 2–5 kuukautta diagnoosin jälkeen. Kysyimme, keille potilaat olivat kertoneet syövästään ja mittasimme heidän terveyteensä liittyvää elämänlaatuaan. Tuloksett: Potilailla oli yleensä runsaasti ihmissuhteita, ja he olivat kertoneet näille syövästään. Lähiverkostojen olemassaolo ja henkilömäärä (puoliso, aikuiset lapset, rintasyöpäpotilailla myös ystävät) olivat yhteydessä huonompaan hyvinvointiin. Sen sijaan tätä kaukaisemmat ihmissuhteet (lasten puolisot, puolison vanhemmat, kaukaisemmat sukulaiset ja muut verkostot, eturauhassyöpäpotilailla myös ystävät) olivat yhteydessä parempaan hyvinvointiin. Päätelmät:. Lähiverkostojen yhteys huonompaan hyvinvointiin saattaa selittyä sillä, että vastasairastuneiden syöpäpotilaiden hyvinvointia kuormittaa huoli läheisimpien hyvinvoinnista. Abstract Background: Social relationships are important resources for health and well-being. These are derived from an individual’s social environment and comprise of social interactions between persons. Social resources have been investigated as social networks, social support, and social capital. Social networks act as sources of social support and are the origins of social capital. Social networks consist of social ties between individuals and groups. We explored newly diagnosed cancer patients’ social networks and investigated their association with the patients’ well-being. Methods: We evaluated breast cancer (n=224) and prostate cancer (n=150) patients’ social networks (existence and person numbers) in the following subnetworks: spouse/partner; family; close relatives, close friends; acquaintances; others with cancer; work community; health professionals; participation (religious, hobby, civic participation) at 2–5 months after diagnosis, and whether they had discussed their cancer with these ties. We measured health-related quality of life and depressive symptoms of the patients and investigated the predictors of these with multivariate analyses. Results: The patients had usually multiple social relationships and had told them about their cancer. Contrary to what had been expected, the strongest ties (spouse/partner and adult children, in breast cancer also friends) were associated with poorer well-being. However, weak ties (spouses of adult children, spouse’s parents, more distant relatives, and extensive social contacts (in breast cancer patients also participation and in prostate cancer patients also friends) predicted better well-being. Conclusions: The association between social networks and well-being depended on the strength of the social subnetwork. Contrary to theories on social support, the strongest ties, i.e., the next of kin, predicted poorer wellbeing. Only weak ties acted as well-being resources. Because of acting as caregivers or worrying about wellbeing of their loved ones, patients with strong social ties may be more burdened and may thus need extra attention.

Published
2020

50. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer

Author

Joensuu, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Bono, Petri, Alanko, Tuomo, Kataja, Vesa, Asola, Raija, Utriainen, Tapio, Kokko, Riitta, Hemminki, Akseli, Tarkkanen, Maija, Turpeenniemi-Hujanen, Taina, Jyrkkio, Sirkku, Flander, Martti, Helle, Leena, Ingalsuo, Seija, Johansson, Kaisu, Jaaskelainen, Anna-Stina, Pajunen, Marjo, Rauhala, Mervi, Kaleva-Kerola, Jaana, Salminen, Tapio, Leinonen, Mika, Elomaa, Inkeri, and Isola, Jorma

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results